Logo

U.S./Finnish Diabetes Research Group Partners with Perlegen

Oct 28, 2002

NEW YORK, Oct. 28-Perlegen will offer its microarray-based SNP genotyping expertise to an international collaborative project that studies the genetics of type 2 diabetes, the company said today.

 

The project, which will seek for diabetes-related genes on the long arm of chromosome 6, involves researchers from the National Human Genome Research Institute, form the National Public Health Institute of Finland, the University of Southern California, and the University of Michigan.

 

This U.S.-Finnish collaboration, after nine years of research, has identified specific regions of the genome that may include genes pertinent to the disease. Working with Perlegen Chief Scientific Officer David Cox, the team will apply the company's chip-based system for high-throughput genotyping to further narrow the focus.

 

Roughly 16 million people in the United States have type 2 diabetes, according to the American Diabetes Association.The disease is thought to be influenced by both genetics and environment.

 

The company did not disclose financial specifics or rights to gene discoveries.

 

Perlegen is an Affymetrix subsidiary.

Breaking News
The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.